France approves antibody therapy for high-risk COVID-19 cases
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration
PARIS — French health authorities have approved the use of an anti-body treatment made by AstraZeneca for high-risk people who show resistance to vaccines against coronavirus.
The independent public health body HAS Friday night announced “a greenlight for the preventive use of Evusheld… for patients with a very high-risk of contracting a severe form of Covid-19”.
Evusheld, developed by the British-Swedish pharma company, this week received emergency use authorisation in the United States for adults and children aged 12 and above.
READ: AstraZeneca COVID-19 antibody drug offers 83% protection over six months
The French approval is for adults only.
Evusheld, which is made from a combination of two monoclonal antibodies, is administered in two injections.
Article continues after this advertisementMonoclonal antibodies — which recognise a specific molecule of the target virus or bacteria — are synthetic versions of natural antibodies.
Article continues after this advertisementUnlike most other Covid treatments, which are given to already hospitalised patients to prevent serious illness, Evusheld is for people who have yet to be infected but may not mount an adequate immune response.
HAS warned of cardiovascular risks identified during clinical trials and recommended the drug not be given to cases with two or more risk factors such as diabetes and obesity.
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
